Hepatic Steatosis
Conditions
Keywords
hepatic steatosis, coffee, fructose, lipids
Brief summary
This study will assess * whether coffee consumption protects against fructose-induced hepatic steatosis in healthy humans * whether the protective effect of coffee is dependent on it's antioxidant composition
Detailed description
Epidemiological studies suggest that coffee consumption improves glucose homeostasis in insulin resistant subjects. An increase in intrahepatic lipids (hepatic steatosis) is highly prevalent in patients with the metabolic syndrome and may be used as a marker of altered hepatic lipid metabolism. Such an increased hepatic lipids content can be experimentally produced in healthy humans by a 6-day high fructose diet. The purpose of this study is to evaluate whether coffee prevents hepatic lipid deposition in healthy male subjects fed a fructose-rich hypercaloric diet. Both caffeine and antioxidants (yet unspecified) may be involved.. To sort out the role of caffeine and antioxidants, we will test 3 different soluble coffee, ie fully torrefied decaffeinated coffee , partially torrefied decaffeinated coffee, and partially torrefied caffeinated coffee.
Interventions
DIETARY_SUPPLEMENTCtl
Control, isocaloric diet; no coffee
DIETARY_SUPPLEMENTHigh fructose diet; no coffee
Hypercaloric, high fructose diet; no coffee
DIETARY_SUPPLEMENTfully torrefied, caffeine-free coffee
Hypercaloric, high fructose diet + coffee
DIETARY_SUPPLEMENTpartially torrefied, caffeine-free coffee
Hypercaloric, high fructose diet + coffee
DIETARY_SUPPLEMENTPartially torrefied, caffeinated coffee
Hypercaloric, high fructose diet + coffee
Sponsors
Nestlé Research Center, Vers-chez-les-blanc, Switzerland
University of Lausanne
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI between 19 and 15 kg/m2 * less than 30 min physical activity /day * habitual coffee consumption less than three cupy /day * consumption of caffeine-containing sodas less than 2 servings/day * non-smoker
Exclusion criteria
* consumption of alcohol more than 40g/day * presence of metallic foreign bodies * history of eye surgery * family history of diabetes mellitus * history of food intolerance * vegetarians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intra-hepatocellular lipid (IHCL) concentration | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
Secondary
| Measure | Time frame |
|---|---|
| fasting net lipid oxidation | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
| fasting net carbohydrate oxidation | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
| fasting plasma triglycerides | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
| whole body glucose turnover (6,6 2H2 glucose) | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
| whole body glycerol turnover (2H5 glycerol) | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
| whole body ketone bodies turnover and oxidation (13C 3-hydroxybutyrate) | will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement |
Countries
Switzerland
Outcome results
None listed